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Haemophilus ducreyi produces a periplasmic copper-zinc superoxide dismutase (Cu-Zn SOD), which is
thought to protect the organism from exogenous reactive oxygen species generated by neutrophils during an
inflammatory response. We had previously identified the gene, sodC, responsible for the production and
secretion of Cu-Zn SOD and constructed an isogenic H. ducreyi strain with a mutation in the sodC gene
(35000HP-sodC-cat). Compared to the parent, the mutant does not survive in the presence of exogenous
superoxide (L. R. San Mateo, M. Hobbs, and T. H. Kawula, Mol. Microbiol. 27:391–404, 1998) and is impaired
in the swine model of H. ducreyi infection (L. R. San Mateo, K. L. Toffer, P. E. Orndorff, and T. H. Kawula,
Infect. Immun. 67:5345–5351, 1999). To test whether Cu-Zn SOD is important for bacterial survival in vivo, six
human volunteers were experimentally infected with 35000HP and 35000HP-sodC-cat and observed for papule
and pustule formation. Papules developed at similar rates at sites inoculated with the mutant or parent. The
pustule formation rates were 75% (95% confidence intervals [CI], 43 to 95%) at 12 parent-inoculated sites and
67% (95% CI, 41 to 88%) at 18 mutant-inoculated sites (P  0.47). There was no significant difference in levels
of H. ducreyi recovery from mutant- and parent-inoculated biopsy sites. These results suggest that expression
of Cu-Zn SOD does not play a major role in the survival of this pathogen in the initial stages of experimental
infection of humans.
Haemophilus ducreyi is the etiologic agent of chancroid, a
common genital ulcer disease found in many developing coun-
tries (7–9, 24, 29, 39). H. ducreyi is a strictly human pathogen
that infects primarily genital and nongenital skin and mucous
membranes. H. ducreyi infection enhances transmission of the
human immunodeficiency virus (HIV) in populations where
both forms of infection are present (17). Understanding the
pathogenesis of chancroid may have implications for control of
both H. ducreyi and HIV infections, especially in Africa and
Southeast Asia (17).
To study H. ducreyi pathogenesis, we developed an experi-
mental infection model with human volunteers (3, 34, 35).
Throughout the papular and pustular stages of experimental
infection, H. ducreyi is surrounded by professional phagocytes
but remains extracellular (5, 6). In vitro, H. ducreyi adheres to
the human macrophage-like cell line U-937 but resists phago-
cytosis (41). Neutrophils usually kill bacteria by ingesting them
or by releasing toxic products such as superoxide radicals and
antimicrobial proteins (10). H. ducreyi replicates during the
initial stages of experimental infection in humans (3, 38), which
suggests that the organism escapes both phagocytosis and kill-
ing by toxic products of neutrophils. How H. ducreyi evades
phagocytic defenses is unclear.
Superoxide dismutases (SODs) are metalloenzymes which
catalyze the conversion of superoxide radicals to oxygen and
hydrogen peroxide. Theoretically, cytoplasmic SODs protect
bacteria from superoxide and H2O2 toxicity generated during
bacterial aerobic metabolism. SODs are highly metal specific,
and cytoplasmic iron (Fe)- and manganese (Mn)-cofactored
SODs are ubiquitous in bacteria (30). Once thought to be rare,
periplasmic copper- and zinc-dependent SODs (Cu-Zn SODs)
have now been described to occur in many bacterial species
(11, 21, 23, 32, 37, 40). The functional significance of the
Cu-Zn SODs in bacterial survival is not fully understood, but
their conservation suggests that the ability to neutralize extra-
cellular superoxide aids the survival of these organisms.
H. ducreyi produces a Cu-Zn SOD that localizes to the
periplasm (21, 30, 36). In vitro, H. ducreyi Cu-Zn SOD does not
complement the growth defect of an Escherichia coli strain that
lacks cytoplasmic SODs, suggesting that the Cu-Zn SOD func-
tions in a compartment different from that in which cytoplas-
mic SODs function (36). H. ducreyi Cu-Zn SOD expressed in
E. coli confers resistance to phagocytic killing by murine
macrophages (4). A Cu-Zn SOD-deficient H. ducreyi strain
(35000HP-sodC-cat) was made by inserting a chloramphenicol
acetyltransferase (cat) cassette into the sodC gene (30).
Though the mutant and parent strains are equally resistant to
induced cytoplasmic reactive oxygen species (ROS), the mu-
tant is significantly more susceptible to killing by pyrogallol-
generated extracellular superoxide (30). When the sodC mu-
tation is complemented in the chromosome, resulting in a
merodiploid (sodCsodC-mutant) strain, parent survival rates
are restored (30).
Cu-Zn SOD may contribute in several ways to the survival of
H. ducreyi. Earlier studies show that H. ducreyi is unable to
synthesize heme and must be supplied with heme or heme-
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containing compounds, such as hemoglobin, for growth (13, 14,
18). Recent data suggest that Cu-Zn SOD binds heme and,
under certain conditions, may protect H. ducreyi from toxic
oxyradicals formed from the reaction of heme iron and oxygen
(25). In addition, the histidine-rich N-terminal region of the
Cu-Zn SOD complex has a high affinity for metals and is
responsible for binding copper, which may be scarce in the
periplasmic space (4). The ability to efficiently sequester cop-
per for eventual delivery to the active site of the enzyme may
enhance the function of the H. ducreyi Cu-Zn SOD (4).
In a swine model, the Cu-Zn SOD-deficient mutant of H.
ducreyi 35000HP causes disease that is similar to that caused by
its parent, as determined by histopathology (31). However, the
mutant is recovered from significantly fewer inoculated sites
and in lower numbers than the parent strain, implying that
Cu-Zn SOD is a virulence factor for this bacterium in this
animal model (31). When pigs are experimentally immunosup-
pressed by treatment with cyclophosphamide, the parent and
mutant H. ducreyi strains survive equally well. These results
suggest that suppression of neutrophil activity may decrease
the generation of superoxide and allow the mutant to survive
normally (31).
In this study, we tested the hypothesis that expression of the
Cu-Zn SOD may be important for bacterial survival in humans.
We compared the ability of a SOD C mutant (35000HP-sodC-
cat) and its isogenic parent, 35000HP, to cause experimental
infection in human volunteers.
MATERIALS AND METHODS
Bacteria.35000HP is a human-passaged variant of 35000 (2, 3, 34). The 35000-
sodC cat mutant, described previously (30), was constructed in 35000HP and has
been renamed 35000HP-sodC-cat here.
OMP and LOS analysis.Lipooligosaccharides (LOS) and outer membrane
proteins (OMP) were prepared from 35000HP and 35000HP-sodC-cat and sub-
jected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis and
silver staining as described previously (27, 42).
Human challenge protocol. Healthy adult male and female volunteers over 18
years of age were recruited for the study. Informed consent was obtained from
the subjects for participation and for HIV serology, in accordance with the
human experimentation guidelines of the U.S. Department of Health and Hu-
man Services and the Institutional Review Board of Indiana University-Purdue
University, Indianapolis. The experimental challenge protocol, preparation and
inoculation of the bacteria, calculation of the estimated delivered dose (EDD),
and clinical observations were done exactly as described previously (1–3, 34, 35).
Each subject was inoculated with two doses (54 to 60 CFU) of live 35000HP and
one dose of heat-killed bacteria on one arm and with three doses (ranging from
30 to 163 CFU) of live 35000HP-sodC-cat on the other arm. Subjects were
observed until they reached a clinical end point, defined as either the develop-
ment of a painful pustule 14 days after inoculation or the resolution of infection
at all sites. When a clinical end point was achieved, the code was broken and up
to two sites with active disease (one inoculated with the parent and one inocu-
lated with the mutant), if present, were biopsied with punch forceps. The subjects
were then treated with two doses of oral ciprofloxacin as described previously.
Surface cultures.For each subject, surface cultures were obtained from all
inoculation sites at each follow-up visit, as described previously (19).
Biopsy specimens. For each subject, a mutant-inoculated site and a parent-
inoculated site were biopsied with punch forceps of the same size. Each biopsy
specimen was cut into halves with a razor blade. One half was fixed in formalin,
and immunohistological studies were done as previously described (26, 34, 35).
The other half was homogenized in 1 ml of freezing medium for 2 min on ice and
cultured semiquantitatively as described previously (34, 35).
Phenotypes of recovered bacteria.Individual colonies from the inocula, surface
cultures, and biopsy specimens were picked, suspended in freezing medium, and
frozen in 96-well plates. The colonies were scored for susceptibility to chloram-
phenicol on chloramphenicol-containing chocolate agar plates. At least 30 indi-
vidual colonies per specimen, if available, were analyzed. If the 30 colonies had
the correct phenotype, then we were confident (95% probability) that, at most,
only 11% of the colonies in a specimen could have had the incorrect phenotype.
RESULTS
Comparison of 35000HP-sodC-cat to 35000HP.The isogenic
mutant 35000HP-sodC-cat was constructed in the 35000HP
background in the laboratory of T. H. Kawula (30). We com-
pared the OMP and LOS profiles and growth rates in the broth
of the 35000HP stock used by members of the S. M. Spinola
laboratory to infect human subjects with 35000HP-sodC-cat.
The OMP and LOS profiles and the growth rates of the strains
were identical (data not shown). Thus, we proceeded with the
human challenge experiments.
Human inoculation experiments. Six healthy adults (four
females, two males; age range, 24 to 51 years; mean age 
standard deviation, 35.8  9.2 years) volunteered for the study.
Three subjects (volunteers 186, 187, and 188) were challenged
in the first iteration, and three subjects (volunteers 190, 191,
and 192) were challenged in the second iteration (Table 1).
An escalating-dose response study was used to compare the
levels of virulence of the mutant and the parent. We initially
inoculated three subjects at six sites on both arms. One arm
was inoculated at three sites with EDDs of 30, 60, and 119
CFU of 35000HP-sodC-cat. The other arm was inoculated at
two sites with EDDs of 60 CFU of the parent and at a third site
with 119 CFU of heat-killed 35000HP-sodC-cat. Papules de-
veloped at six of six sites inoculated with the parent and at
seven of nine sites inoculated with the mutant. At end point,
pustules developed at five of six sites inoculated with the par-
ent and at four of nine sites inoculated with the mutant (Table
1).
Since the mutant was not impaired in its ability to cause
pustules, we infected three more subjects to confirm these
results. Our goal was to inoculate this group of subjects with

















186 6 35000HP 2 2
35000HP-sodC-cat 1 1
187 9 35000HP 2 2
35000HP-sodC-cat 3 3
188 9 35000HP 2 1 1
35000HP-sodC-cat 3 1 2
190 10 35000HP 2 1 1
35000HP-sodC-cat 3 2 1
191 7 35000HP 2 1 1
35000HP-sodC-cat 3 3
192 7 35000HP 2 2
35000HP-sodC-cat 3 3
a Each volunteer was inoculated at two sites with the parent (35000HP) and at
three sites with the mutant (35000HP-sodC-cat). Volunteers 186, 187, and 188
were inoculated in the first iteration, and volunteers 190, 191, and 192 were
inoculated in the second iteration.
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EDDs similar to those from the first iteration. Three sites were
inoculated with EDDs of 41, 82, and 163 CFU of 35000HP-
sodC-cat. Two sites were inoculated with 54 CFU of the parent,
and a third site was inoculated with 163 CFU of heat-killed
35000HP-sodC-cat. Six of six parent-inoculated sites and nine
of nine mutant-inoculated sites developed papules (Table 1).
At clinical end point, pustules developed at four of six parent-
inoculated sites and at eight of nine mutant-inoculated sites.
Thus, 35000HP-sodC-cat was not impaired in its ability to form
pustules.
The cumulative results for the two iterations showed that
papules developed at 100% (exact-binomial 95% confidence
intervals [CI], 74 to 100%) of 12 sites inoculated with 35000HP
and at 89% (exact-binomial 95% CI, 65 to 99%) of 18 sites
inoculated with 35000HP-sodC-cat (one-tailed Fisher’s exact
test, P  0.35). Thus, the mutant was not impaired in its ability
to cause disease in human volunteers. Pustules formed at 9 of
12 (75%; exact-binomial 95% CI, 43 to 95%) sites inoculated
with 35000HP compared to 12 of 18 (67%; exact-binomial 95%
CI, 41 to 88%) sites inoculated with 35000HP-sodC-cat (one-
tailed Fisher’s exact test, P  0.47). Therefore, the mutant was
not impaired in its ability to form pustules compared to the
parent. For both iterations, small papules formed initially at
three of six heat-killed control sites but resolved within 1 to 2
days, confirming that pustule formation was due to the inocu-
lation of live bacteria.
Bacterial recovery and cellular infiltrate from mutant and
parent lesions.Surface cultures were obtained by swabbing in-
oculation sites at each follow-up visit. No bacteria were recov-
ered from sites inoculated with the heat-killed control. Of 78
cultures of parent-inoculated sites, three positive surface cul-
tures with 42 colonies were recovered. Four surface cultures
from a total of 117 cultures of mutant-inoculated sites were
positive, and 32 colonies of 35000HP-sodC-cat were recovered.
In the swine model of infection, a sodC-deficient H. ducreyi
strain was recovered from significantly fewer inoculated sites
than the parent strain (31). By quantifying the number of
bacteria present in halved biopsy specimens, the mutant was
also less numerous in swine lesions than the parent (31). In this
trial, H. ducreyi cells were recovered from five subjects who had
parent- and mutant-inoculated sites that contained pustules at
end point. H. ducreyi cells were recovered from all five parent
biopsy samples (range, 6.2  102 to 2.7  106 CFU per g of
tissue; mean  standard deviation, 9.0  105  1.1  106 CFU
per g of tissue) and all five mutant biopsy samples (range, 8.8 
103 to 1.2  106 CFU per g of tissue; mean  standard devi-
ation, 1.5  105  2.4  105 CFU per g of tissue). In contrast
to the swine model, there was no significant difference between
the numbers of H. ducreyi cells recovered from parent and
mutant biopsy specimens (paired t test after log transforma-
tion, P  0.72).
In the swine model, the cellular infiltrates of mutant and
parent biopsy samples were similar when they were analyzed by
immunohistochemistry (31). Here, we also examined the cel-
lular infiltrates in five parent and five mutant pustules. Micro-
pustules with polymorphonuclear leukocytes (PMNs) were
present in the epidermis of specimens from the subjects inoc-
ulated with the parent and mutant (data not shown). The
dermis contained a perivascular infiltrate of mononuclear cells
and some PMNs, and the venules were lined with reactive
endothelial cells. The majority of mononuclear cells stained
positively with a CD3 marker (data not shown). Thus, similar
to what occurred in the swine model of infection, there were no
notable differences between mutant and parent samples when
they were analyzed by immunohistochemistry.
Confirmation of the phenotype of the recovered bacteria.To
confirm that the inocula were correct and that no cross-con-
tamination of sites had occurred during infection, individual
colonies from each of the broth cultures used to prepare the
inocula, from surface cultures and from biopsy specimens,
were analyzed for chloramphenicol susceptibility. For the two
parent and two mutant broth cultures used to prepare the
inocula, all 96 parent colonies and all 96 mutant colonies tested
were phenotypically correct (mutant, Cmr; parent, Cms). All 42
colonies obtained from surface cultures of parent-inoculated
sites and all 32 colonies from surface cultures of mutant-inoc-
ulated sites were phenotypically correct. All 108 parent colo-
nies and 176 mutant colonies obtained from biopsy samples
were phenotypically correct. Thus, all colonies tested from the
inocula, surface cultures, and biopsy specimens had the ex-
pected antibiotic susceptibility.
DISCUSSION
In this study, we tested the ability of an isogenic sodC-
deficient mutant (35000HP-sodC-cat) to infect human volun-
teers. In our volunteer group, the mutant formed papules at a
rate similar to that of the parent. Pustules also formed at
similar rates at mutant- and parent-inoculated sites, and halved
biopsy specimens of mutant and parent pustules contained
similar numbers of bacteria. Taken together, the data suggest
that sodC activity is not a major factor in the ability of H.
ducreyi to survive and cause disease during the initial stages of
experimental infection of humans.
The bactericidal activities of neutrophils and macrophages
are attributed in part to an induced oxidative burst upon ex-
posure to bacteria (10). Activation of enzymes responsible for
the respiratory burst depends on stimulation by a number of
factors, including phagocytosis (10). In vitro, Cu-Zn SODs of a
variety of organisms have been found to confer resistance to
killing by detoxifying ROS generated by the oxidative burst (4,
28, 32, 33). In animal models, Cu-Zn SODs have a role in
bacterial survival for some organisms (11, 15, 16, 31, 40) but
not others (12, 23, 28, 33). Many of these data come from
models which utilize animals that are not the natural hosts of
the test organism. Thus, whether survival and/or virulence in
animal models reflects altered host-bacterium interactions or
the actual role of Cu-Zn SODs in virulence is unclear.
Previous studies that have evaluated Cu-Zn SOD mutants in
models that utilize natural hosts include Salmonella enterica
serovar Typhimurium and Actinobacillus pleuropneumoniae
(11, 15, 16, 33). S. enterica serovar Typhimurium contains two
distinct sodC genes (15). In a murine peritoneal infection
model, the wild-type strain of S. enterica serovar Typhimurium
causes a 50% mortality rate 6 to 7 days after inoculation (11,
15). A mutant that had both sodC genes inactivated was less
lethal than the parent or than mutants having one intact sodC
gene (15). In contrast, there is no difference in the abilities of
wild-type and Cu-Zn SOD-deficient mutant strains of A. pleu-
ropneumoniae to cause respiratory disease 42 h after inocula-
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tion into the lungs of swine (33). The histopathology of the
pulmonary lesions in pigs infected with the sodC-deficient mu-
tant is the same as that of lesions caused by the parent strain
(33).
The different contributions that Cu-Zn SODs make to S.
serovar Typhimurium and A. pleuropneumoniae pathogenesis
in their respective models may reflect an inherent difference in
the way these two pathogens interact with phagocytic cells in
their natural hosts. S. enterica serovar Typhimurium is a fac-
ultative intracellular organism. Macrophage killing of Salmo-
nella spp. involves bacterial uptake and the combined effects of
NADPH oxidase (the respiratory burst) and inducible nitric
oxide (NO) synthase (11). These toxic radicals are active over
short distances and need to be sequestered and/or concen-
trated in phagosomes to be effective in bacterial killing. After
S. enterica serovar Typhimurium is phagocytosed, activated
radicals produced by NADPH oxidase and NO synthase may
induce cell damage by crossing the bacterial outer cell mem-
brane and accumulating in the periplasmic space (11). De-
Groote and colleagues proposed that Cu-Zn SOD protects S.
enterica serovar Typhimurium by neutralizing these toxic prod-
ucts, thereby decreasing their local concentration within the
periplasm (11). In contrast, A. pleuropneumoniae causes dis-
ease primarily as an extracellular pathogen (11, 33). SOD ac-
tivity may be less critical to the survival of A. pleuropneumoniae
because toxins released during the respiratory burst dissipate
when they are released into the extracellular compartment. A.
pleuropneumoniae cells probably survive host defenses primar-
ily by evading phagocytosis and secreting cytolytic toxins (Apx
I and II) that lyse neutrophils rather than by detoxifying ROS
by Cu-Zn SOD activity (33).
Although Cu-Zn SOD has a role in the survival of S. enterica
serovar Typhimurium in a short-term-infection model, its im-
portance for other intracellular pathogens in the setting of
chronic infection is not clear. For example, a Cu-Zn SOD-
deficient mutant of Mycobacterium tuberculosis survives as well
as the parent in a murine lung infection model 60 days after
inoculation and in guinea pigs 35 days after subcutaneous
injection (12, 28). Piddington and coworkers speculate that
sodA may compensate for the loss of sodC during chronic
infection (28). Alternatively, M. tuberculosis may not activate
macrophages in vivo and may stimulate a vigorous respiratory
burst (28), diminishing the potential role of Cu-Zn SOD for
survival in these models.
To our knowledge, this study is the first evaluation of a
Cu-Zn SOD mutant in humans. We did not detect differences
between 35000HP and 35000HP-sodC-cat in terms of disease
establishment, progression, and bacterial recovery after exper-
imental infection. In vitro, H. ducreyi is phagocytosed by puri-
fied PMNs (22) but it resists phagocytosis by the macrophage
cell line U-937 (41). Confocal microscopic studies show that H.
ducreyi colocalizes with PMNs and macrophages but remains
extracellular throughout experimental infection of human vol-
unteers (5). Since H. ducreyi appears to resist engulfment, we
speculate that the bacteria may not stimulate the respiratory
burst in the human infection model. Alternatively, because H.
ducreyi remains extracellular, any released toxins may not be
concentrated enough to harm the bacteria. Our results parallel
the findings from the swine model of acute A. pleuropneumo-
niae infection and are consistent with our observation that H.
ducreyi causes disease primarily as an extracellular pathogen in
the experimental infection of humans.
Analyses of mutant and parent biopsy specimens in our
experiments did not show a difference in the numbers of mu-
tant and parent bacteria recovered from pustules. Our results
are in contrast to those noted from the swine model of H.
ducreyi infection, in which the sodC mutant was recovered from
fewer inoculated sites and in fewer numbers than the parent
(31). The swine model and the human challenge model are
similar in that Multi-Test applicators are used to deliver the
bacteria to the skin of test subjects or animals. The histopathol-
ogies of experimental swine and human lesions are also similar
(26, 33). However, the EDD used in the human model is on the
order of 101 CFU, while the EDD used in the swine model is
approximately 104 CFU. The larger EDD required for infec-
tion in the swine model suggests that H. ducreyi is a less effi-
cient pathogen for pigs than for humans and that the absence
of a candidate virulence determinant may have a more pro-
nounced effect in swine than in humans. In the human model,
H. ducreyi achieves a density of 105 CFU/lesion at the pustular
stage, approximately 1 week after inoculation (38). In the
swine model, the number of bacteria decreases from 1.7  104
CFU to 1.7  103 CFU 48 h after inoculation. Despite this
initial decrease, H. ducreyi persists in swine lesions for weeks
(20). Immunosuppression of swine with cyclophosphamide al-
lows the Cu-Zn SOD mutant and the parent to achieve den-
sities of 2.7  105 and 1.2  104, respectively, 48 h after
inoculation (31). These findings suggest that swine neutrophils
may be more efficient at clearing H. ducreyi than human neu-
trophils in the initial stages of infection.
In summary, our data show that expression of sodC is not
required for the survival and virulence of H. ducreyi during
experimental infection of human volunteers. Cu-Zn SOD may
play a major role in bacterial survival for microbes that are
phagocytosed and activate the respiratory burst. H. ducreyi
appears to evade phagocytosis in the initial stages of experi-
mental infection of humans, which may minimize the contri-
bution of Cu-Zn SOD activity to pathogenesis in this model.
For subject safety considerations, we did not allow experimen-
tal infection to progress beyond 14 days or to the ulcerative
stage of disease. Whether H. ducreyi is engulfed by professional
phagocytes during natural or later stages of infection is un-
known, and we cannot test whether Cu-Zn SOD has a role in
pathogenesis later in infection. Future studies should focus on
examining whether the interactions between H. ducreyi and
professional phagocytes change during the course of human
infection and whether H. ducreyi interacts differently with
swine neutrophils than with human neutrophils.
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